A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-α2a as first line treatment in metastatic melanoma

Pia P. Vihinen, Micaela Hernberg, Meri-Sisko Vuoristo, Kristiina Tyynelä, Marjut Laukka, Johan Lundin, Johanna Ivaska, Seppo Pyrhönen

Research output: Contribution to journalArticleScientificpeer-review

46 Citations (Scopus)

Fingerprint Dive into the research topics of 'A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-α2a as first line treatment in metastatic melanoma'. Together they form a unique fingerprint.

Medicine & Life Sciences